- Automated Collection and Analysis of Bioreactor Samples to Enable Quality by Design InitiativesPosted 21 hours ago
- Development of Animal-free Peptones for Mammalian and Microbial CulturePosted 1 week ago
- Cool Tool – Fluid Transfer Sets Specifically Designed for Sterile Transfer of Cell Therapy Based ProductsPosted 1 week ago
- Electroporation-based Transfection Demonstrates Consistent Antibody Quality and Glycosylation Patterns for Biotherapeutic Product DevelopmentPosted 1 month ago
- Cool Tool – Cell Culture Basics Virtual LabPosted 1 month ago
- Video – Bioprocessing pH Probe Selection and MaintenancePosted 1 month ago
- Cool Tool – Kits to Simplify and Standardize Your Immune Cell CulturesPosted 1 month ago
- Cool Tool – An Optimized, Chemically-Defined, Animal Component-Free Neural Basal MediumPosted 1 month ago
- Cool Tool – Lynx CDR Connectors to Improve Sterile Fluid Transfer in BiomanufacturingPosted 1 month ago
- Improving Glycosylation Patterns and Consistency Through Media OptimizationPosted 1 month ago
The future of cell culture development? Part II
GEN has a new article that touches on post translational modifications, which one of the major issues facing biomanufacturers, especially those that produce (or hope to produce) biosimilars. As usual glycosylation is the major theme, but the author also touches on deamidation.
Some of the different technologies mentioned include yeast glycoengineering (GlycoFi), a CHO/DG44 line that produces fucose-free antibodies by knocking out the key fucose-adding enzyme (Potelligent cell line), and the greenovation system that uses phototautotrophic moss (add moss to the ever-growing list of organisms currently being pursued as a biopharmaceutical production host organism!).
These are interesting approaches to solve complex problems, but as I have mentioned before, when will any of these type of technologies be used in FDA approved processes? There have been numerous technologies that have tried to vastly improve on the current CHO paradigm (Per.C6 anyone?), but the industry can sometimes be very slow to move, especially when the current system isn’t broken. Many companies instead look to their different development groups (API, cell line, upstream, etc.) and make advances in cell culture media (using supplements or optimized nutrient feeds) , cell lines, and downstream processes instead of switching to a new host organism. It’s difficult to prognosticate which approach will be best, but what do you think will win out?